oltipraz has been researched along with Prostatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, Y; Dai, YQ; Fan, BY; Gu, J | 1 |
| Boone, CW; Christov, KT; Kelloff, GJ; Lantvit, DD; Lubet, RA; Moon, RC; Pezzuto, JM; Steele, VE | 1 |
2 other study(ies) available for oltipraz and Prostatic Neoplasms
| Article | Year |
|---|---|
Stanniocalcin1 knockdown induces ferroptosis and suppresses glycolysis in prostate cancer via the Nrf2 pathway.
Topics: Ferroptosis; Glucose; Glycolysis; Humans; Lactates; Male; NF-E2-Related Factor 2; Prostatic Neoplasms | 2022 |
Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies.
Topics: Animals; Antineoplastic Agents; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Eflornithine; Estradiol; Male; Models, Animal; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Pyrazines; Rats; Rats, Inbred Strains; Testosterone; Thiones; Thiophenes; Time Factors | 2004 |